Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale

IMPORTANCE: Recently, anticancer agents have generated excitement owing to their capacity to preserve long-term durable survival in some patients who are represented by a tail of the survival curve. However, because traditional measures of clinical benefit may not accurately capture durable survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Everest, Louis, Shah, Monica, Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624800/
https://www.ncbi.nlm.nih.gov/pubmed/31290990
http://dx.doi.org/10.1001/jamanetworkopen.2019.6803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624800/
https://www.ncbi.nlm.nih.gov/pubmed/31290990
http://dx.doi.org/10.1001/jamanetworkopen.2019.6803

Ejemplares similares